Harte Hanks Reports Q1 2026 Revenue Decline and Increased Losses; Cash Balance Remains Strong
HHS sits 27% above its 52-week low of $2.22.
Summary
Harte Hanks announced Q1 2026 financial results showing a 10.3% revenue decrease and worsening profitability, though the company highlighted its strong cash position and ongoing strategic alignment.
Key Events · Earnings and Guidance · HHS
-
Revenue Decline
Total revenues for Q1 2026 were $37.3 million, a 10.3% decrease compared to $41.6 million in Q1 2025.
-
Increased Operating and Net Losses
Operating loss widened to $768 thousand from $40 thousand in the prior year, and net loss increased to $0.6 million from $0.4 million.
-
EBITDA Significantly Lower
EBITDA for Q1 2026 was $0.3 million, down from $1.0 million in Q1 2025. Adjusted EBITDA also fell to $0.7 million from $1.8 million.
-
Strong Balance Sheet Maintained
The company ended the quarter with a cash balance of $4.5 million and no outstanding debt, providing financial stability despite operational challenges.
Analysis · HHS · Trade & Services
Harte Hanks reported a significant 10.3% year-over-year revenue decline for Q1 2026, alongside increased operating and net losses, and a substantial drop in EBITDA. While these results indicate ongoing financial challenges, the company maintains a strong balance sheet with $4.5 million in cash and no outstanding debt, which provides a buffer as it pursues its growth strategy.
At the time of this filing, HHS was trading at $2.81 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $20.8M. The 52-week trading range was $2.22 to $5.39. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.